Recommendation of the President – Trodelvy (sacituzumab govitecan)
On 25 July 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 100/2025 on the inclusion of the medicinal product Trodelvy (sacituzumab govitecan) in the B.9.FM drug program. “Treatment of patients with breast cancer (ICD-10: C50)”